Following ward round on 10 November, please find below some further reading on anticoagulation for patients with catheter-related thrombosis.
| Please note that inclusion in this blog is not an endorsement of quality. Please follow local protocols for drug doses. To access full text you will need an NHS OpenAthens account. Please sign up here if you haven’t already got one. KnowledgeShare is a current awareness tool which helps you deal with information overload, while ensuring that you receive high quality information on topics that are important to you. Take five minutes to fill in this form and we will send you regular updates on your chosen topic. |
Guideline
Association of Anaesthetists guidelines: safe vascular access 2025 See especially the final part of the section on ‘coagulopathies, anticoagulation and catheter-related venous thrombosis’ on page 12 in the PDF
DynaMed
DynaMed (2026) Catheter-Related Thrombosis
See especially the following sections:
Catheter-Related Thrombosis > Overview and Recommendations > Management > Therapy of Established Catheter-Related Thrombosis
Catheter-Related Thrombosis > Management > Medications > Anticoagulants
Articles
1. Risk Factors for Catheter-Related Thrombosis
Authors: La Cava, Leyla; Giustivi, Davide; Bartoli, Arianna, et al
Publication Date: 2026
Journal: Journal of Clinical Medicine 15(10), pp.3932. doi: 10.3390/jcm15103932
Abstract: Background: Although guidelines emphasize proper insertion techniques and tip positioning, catheter-related thrombosis (CRT) remains a common and clinically significant complication of peripherally inserted central catheters (PICCs) and midline catheters (MCs). In this context, the use of pharmacological prophylaxis is still debated. This study aims to assess the incidence of CRT in patients receiving anticoagulant therapy (therapeutic or prophylactic) and antiplatelet therapy. Methods: This retrospective study was conducted at a tertiary care hospital and included adult patients from March 2021 to May 2023. Six potential confounders were analyzed: anticoagulation status (none, prophylaxis, therapeutic), antiplatelet therapy, tip position (PICCs vs. MCs), number of lumens, CRT risk factors, and drug infusion requiring central access. CRT was diagnosed in symptomatic patients using compression ultrasonography. Propensity score weighting and logistic regression were employed to estimate odds ratios (OR) and average treatment effects. Results: A total of 1431 patients were enrolled. PICCs and therapeutic anticoagulant therapy were highly protective against CRT (OR 0.068 [95% CI 0.013-0.2] and OR 0.007 [95% CI 0.001-0.046], respectively). Prophylactic anticoagulant therapy (OR 0.328 [95% CI 0.200-0.519]) and antiplatelet therapy (OR 0.342 [95% CI 0.182-0.595]) also showed protective effects. At the same time, neither the number of lumens, the presence of risk factors, nor the infusion of irritating drugs was independently associated with CRT. Conclusions: The use of anticoagulant drugs (both prophylactic and therapeutic), antiplatelet therapy, and PICC use significantly lowered the risk of CRT. The findings support personalized prevention strategies and underscore the need for a well-designed randomized controlled trial to validate these findings.
Access full text https://libkey.io/10.3390/jcm15103932
2. Treatment of catheter related thrombosis: A systematic review, meta-analysis, and national survey
Authors: Oomen, Laurens A.; van Diest, Janette; Lucas, Felice R. M., et al
Publication Date: 2026
Journal: Journal of Vascular Surgery.Venous and Lymphatic Disorders 14(2), pp.102359
Abstract: BACKGROUND: Catheter-related thrombosis (CRT) is a known complication of central venous catheters and peripherally inserted central catheters, yet optimal treatment remains uncertain. We conducted a systematic review and national survey to assess current CRT management strategies. METHODS: Following the PRISMA guidelines, we searched three databases through October 2024 for studies on CRT associated with central venous catheters or peripherally inserted central catheters. Meta-analyses and subgroup analyses were performed by anticoagulant type. A national survey among Dutch intensive care and hematology physicians explored current treatment practices. RESULTS: Of 4123 records screened, 34 observational studies were included, mostly involving patients with cancer. The venous thromboembolism recurrence rate per 100 patient-years was higher in patients with cancer (14.1; 95% confidence interval, 11.4- 17.4; I(2) = 35.1) vs patients without cancer (2.0; 95% confidence interval, 0.6-6.0; I(2) = 10.3; P = .0002). Recurrence was comparable between direct oral anticoagulants (DOACs) and low-molecular-weight heparin/vitamin K antagonists (LMWH/VKAs), at 11.0 vs 7.6 (P = .14). Major bleeding occurred in 10.5 vs 13.1 (P = .45), and clinically relevant nonmajor bleeding in 26.2 vs. 22.4 (P = .70), for DOACs vs LMWH/VKAs, respectively. All studies were observational, most at high risk of bias. Survey data showed LMWH was preferred for symptomatic CRT (50%), with treatment lasting 8 days to 6 months. In asymptomatic CRT, anticoagulant type and duration were left to physician discretion in 64% of cases. CONCLUSIONS: Treatment with LMWH/VKA or DOACs shows similarly low venous thromboembolism recurrence, although rates are higher in patients with cancer. Bleeding was substantial and comparable across therapies. Evidence is limited by observational bias. Survey data show that LMWH predominates for CRT, with variable duration. Well-designed randomized controlled trials are warranted.
Access full text https://libkey.io/10.1016/j.jvsv.2025.102359
3. Critical Review of International Clinical Practice Guidelines Recommendations for Prevention, Diagnosis, and Management of Central Venous Catheter Thrombosis
Authors: Rosson, Marco; D’Oria, Mario; Simion, Chiara, et al
Publication Date: 2026a
Journal: Thrombosis and Haemostasis 126(6), pp.553–567
Abstract: Central venous catheters (CVCs) are widely used in clinical practice for the administration of medications, parenteral nutrition, and hemodynamic monitoring. However, their use is associated with a significant risk of thrombosis, which can lead to serious complications, including catheter dysfunction, infection, and embolism. Numerous international clinical practice guidelines (CPGs) have been developed to address the prevention, diagnosis, and management of CVC-related thrombosis. This critical review aims to evaluate and compare the recommendations provided by these guidelines, highlighting areas of consensus, variation, and potential gaps. We systematically analyzed CPGs from major healthcare organizations, focusing on key aspects such as risk stratification, prophylactic strategies, diagnostic algorithms, and therapeutic interventions. Although most guidelines emphasize the importance of risk assessment and early intervention, there are notable discrepancies in recommendations regarding the use of anticoagulant prophylaxis, imaging modalities for diagnosis, and the duration of anticoagulation therapy. Additionally, the review explores the evidence underpinning these recommendations and identifies areas where robust clinical data are lacking. Our analysis underscores the need for harmonization across guidelines to ensure consistent and evidence-based care. Furthermore, we advocate for the development of multidisciplinary approaches to enhance decision-making and optimize clinical outcomes in this domain. By addressing the gaps and inconsistencies in current CPGs, this review seeks to provide a framework for improving the prevention, diagnosis, and management of CVC-related thrombosis, ultimately enhancing patient outcomes and reducing the healthcare burden.
Request full text https://libkey.io/10.1055/a-2649-9451
4. Utilizing evidence-based diagnosis and treatment for central venous thrombosis: closing the gaps where guidelines fail
Authors: Rosson, Marco; D’Oria, Mario; Simion, Chiara, et al
Publication Date: 2026b
Journal: Expert Review of Hematology, pp.1–12
Abstract: INTRODUCTION: Catheter-related thrombosis (CRT) is a frequent complication of central venous catheters and accounts for most upper extremity deep vein thrombosis events. Despite its increasing clinical burden, management remains poorly standardized because recommendations are largely extrapolated from general venous thromboembolism studies rather than CRT-specific evidence. AREAS COVERED: We performed a structured comparative review of major international, European, and North American guidelines, consensus documents, and position statements identified through PubMed, Ovid, and Scopus searches covering January 2016 to March 2026. Nineteen documents from vascular medicine, oncology, and vascular access societies were included. Recommendations on diagnostic strategies, imaging modalities, catheter management, anticoagulant selection, treatment duration, and invasive interventions were systematically compared. EXPERT OPINION: Considerable heterogeneity persists across recommendations. Ultrasound is consistently endorsed as the first-line imaging modality, whereas the role of clinical prediction scores and D-dimer remains uncertain because neither has been validated in CRT populations. Catheters should be preserved when functional, correctly positioned, and free from infection. Anticoagulation for at least 3 months is universally recommended, while invasive procedures should be reserved for selected patients with extensive thrombosis or life- or limb-threatening complications. Prospective studies are urgently needed to validate diagnostic algorithms, optimize anticoagulant strategies, and develop CRT-specific evidence-based pathways.
Access full text https://libkey.io/10.1080/17474086.2026.2755169
5. Catheter-related deep vein thrombosis: Where are we at and where are we going? Updates and ongoing unmet clinical needs
Authors: Girardi, Laura; Di Nisio, Marcello; Candeloro, Matteo, et al
Publication Date: 2025
Journal: European Journal of Clinical Investigation 55(1), pp.e14311
Abstract: BACKGROUND: Catheter-related thrombosis (CRT) is one of the major complications affecting patients with indwelling venous catheters, usually involving the upper extremity deep venous system. This condition can lead to potentially life-threatening complications such as pulmonary embolism and sepsis. The risk of developing CRT varies depending on type of catheters and patient characteristics. Despite advances in materials and technologies, the actual incidence of CRT is still considerable. Available evidence on CRT management remains controversial, and clinical guidelines base their recommendations on data from non-catheter related upper extremity or lower extremity deep venous thromboses. AIMS: This narrative review aims to describe the epidemiology of CRT, to review the available evidence on its management and to highlight the current unmet needs. METHODS: No formal search strategy was applied for the revision of the literature. The main sources of information used were Medline and guidelines from international societies. CONTENT: The management of CRT requires a careful balance between the risk of thrombus progression, recurrent events, and systemic embolization and the increased bleeding risk in often fragile patients. Open issues include the optimal management of the catheter and the type and duration of anticoagulant therapy. Direct oral anticoagulants are increasingly prescribed, representing an important alternative to the standard of care low molecular weight heparins in selected cases. The development of new anticoagulant drugs such as factors XI and XII inhibitors may offer further advantages in this context. CONCLUSIONS: The management of CRT is still challenging with constant need for updated evidence to support tailored approaches.
Access full text https://libkey.io/10.1111/eci.14311
6. Unveiling the complexities of catheter-related thrombosis: risk factors, preventive strategies, and management
Authors: King, Hannah L.; Padilla-Lazos, Thalia; Chitkara, Akshit, et al
Publication Date: 2025
Journal: Journal of Thrombosis and Thrombolysis 58(3), pp.443–457
Abstract: Catheter-related deep venous thrombosis (CR-DVT) is a common complication of central venous catheters, however optimal prophylactic and treatment strategies have yet to be fully defined. While the use of anticoagulation for CR-DVT prophylaxis is not routinely recommended, current available data offer heterogeneous results due to small sample size, non-uniform study design, and varying comorbid conditions. Available guidelines for the treatment of CR-DVT generally recommend a limited duration of anticoagulation after catheter removal. If ongoing use is required and the device remains functional, guidelines support anticoagulation throughout the time the catheter remains in place. It is worth acknowledging that data guiding these recommendations is largely derived from observational studies of upper extremity CR-DVT, along with randomized trials of anticoagulation in patients with lower extremity DVT. Therefore, large, randomized controlled trials are desperately needed to define optimal management, especially in patients who are at high risk for bleeding. This review explores the epidemiology and risk factors of CR-DVT, diagnostic, prophylactic and treatment strategies, guideline recommendations, and future advances in the field, including the introduction of novel anticoagulants. With current available evidence, we also conclude with an individualized approach to preventing and managing CR-DVT to assist clinicians who are faced with this common clinical scenario.
Access full text https://libkey.io/10.1007/s11239-025-03073-7
7. A Comprehensive Review of Catheter-Related Thrombosis
Authors: López-Rubio, Marina; Lago-Rodríguez, Marta-Olimpia; Ordieres-Ortega, Lucía, et al
Publication Date: 2024
Journal: Journal of Clinical Medicine 13(24), pp.7818. doi: 10.3390/jcm13247818
Abstract: Catheter-related thrombosis (CRT) is a frequent and potentially serious complication associated with the widespread use of intravascular devices such as central venous catheters, including peripherally inserted central catheters and implantable port systems, pacemakers or implantable cardioverter-defibrillators. Although CRT management has been informed by guidelines extrapolated from lower extremity deep vein thrombosis (DVT), unique challenges remain due to the distinct anatomical, pathophysiological, and clinical characteristics of upper extremity DVT. Risk factors for CRT are multifactorial, encompassing patient-related characteristics such as cancer, prior venous thromboembolism, and infection, as well as catheter-specific factors like device type, lumens, and insertion site. The diagnosis of CRT relies primarily on ultrasonography; however, computed tomography angiography and magnetic resonance imaging play a complementary role, particularly in anatomically challenging cases or when complications such as pulmonary embolism or superior vena cava syndrome are suspected. Treatment strategies for CRT include anticoagulation, catheter removal when feasible, and, in select cases, local thrombolysis or catheter-directed interventions. Anticoagulation remains the cornerstone of therapy, with direct oral anticoagulants increasingly favored due to their safety profile and efficacy. This article provides a detailed review of CRT, focusing on clinical features, diagnostic methods, and treatment strategies while addressing specific challenges in managing pacemaker and hemodialysis catheter-related thrombosis.
Access full text https://libkey.io/10.3390/jcm13247818